• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Intercure Ltd.

    6/15/26 9:30:49 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INCR alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

     

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

     

    For the month of June 2026

     

    Commission File Number: 001-40614

     

    INTERCURE LTD.

    (Translation of registrant’s name into English)

     

    85 Medinat ha-Yehudim Street

    Herzliya, 4676670, Israel

    Tel: +972 77 460 5012

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     
     

     

    On June 15, 2026, InterCure Ltd. issued a press release titled “InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.

     

    Exhibit No.    
    99.1   Press Release issued by InterCure Ltd. on June 15, 2026, titled “InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition.”

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      INTERCURE LTD.
       
    Date: June 15, 2026 /s/ Amos Cohen
      Amos Cohen
      Chief Financial Officer

     

     

     

     

     

    Get the next $INCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INCR

    DatePrice TargetRatingAnalyst
    5/18/2022$13.00Speculative Buy → Buy
    Canaccord Genuity
    More analyst ratings

    $INCR
    SEC Filings

    View All

    SEC Form 6-K filed by Intercure Ltd.

    6-K - Intercure Ltd. (0001857030) (Filer)

    6/22/26 9:04:57 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Intercure Ltd.

    6-K - Intercure Ltd. (0001857030) (Filer)

    6/15/26 9:30:49 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Intercure Ltd.

    6-K - Intercure Ltd. (0001857030) (Filer)

    5/1/26 6:04:47 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds

     ●The funding includes investments commitments from key shareholders of the Company, including the Company’s CEO Alexander Rabinovich, as well as leading pharma-focused hedge funds, including Bennu Pharma Fund Ltd., managed by Mr. Ori Hershkovitz.  ●The funding may increase to NIS 54 million to support the Company’s global expansion, including growing demand in Germany and opportunities in regulated U.S. medical cannabis markets. NEW YORK & HERZLIYA, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), today announced that, further to the Company’s prior reports regarding growing demand in Germany and opportunitie

    6/22/26 8:50:00 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition

    First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets. NEW YORK and HERZLIYA, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced the successful completion of the first tranche of its acquisition of Botanico Ltd. ("Botanico"), also known as ISHI, an Israeli cannabis technology and brand company.  Following the recent U.S. federal rescheduling of certain state-licensed medical cann

    6/15/26 9:25:00 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow

    The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent profitability, with a twelfth consecutive half-year of positive Adjusted EBITDA, as the Company continues to recover from the impact of the October 7, 2023 events  NEW YORK and HERZLIYA, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company"), today announced its financial and operating results for 2025. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. FY2025 Financial Highlights and Milest

    4/30/26 6:05:00 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InterCure upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00

    5/18/22 7:21:05 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Rabinovich Alexander

    3 - Intercure Ltd. (0001857030) (Issuer)

    4/20/26 4:01:14 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Michelson Lennie Grinbaum

    3 - Intercure Ltd. (0001857030) (Issuer)

    4/20/26 4:01:17 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Granot Alon Shmuel

    3 - Intercure Ltd. (0001857030) (Issuer)

    4/20/26 4:01:16 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Intercure Ltd.

    SC 13G - Intercure Ltd. (0001857030) (Subject)

    5/16/22 1:02:53 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Financials

    Live finance-specific insights

    View All

    InterCure Reschedules 2022 Full Year Results Conference Call

    NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022. The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen circumstances which caused technical issues. Participants can access the live webcast and conference call through the following link: https://register.vevent.com/register/BIdec7603751894ebcbf0f22eca9

    4/3/23 3:27:01 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

    Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from operations Strong balance sheet with over $95 million cash NEW YORK, TORONTO, and HERZLIYA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted. Full Year 2022 Key Financial & Operating High

    3/31/23 8:00:49 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Reports Record Breaking Second Quarter Financial Results

    Record revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable growth Eighth consecutive quarter of positive cash flow from operations $96 million cash on hand Revenue growth expected to continue in the third quarter and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial results

    8/15/22 9:15:00 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care